DPCP for the Treatment of Alopecia Areata

NCT03651752 | Terminated Phase 3 Results DMC FDA Drug

• 1 other identifier: DERM-2016-25380
• Study Type: interventional
• Target: 4
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open labeled study to determine the response and characteristics, safety and efficacy, of the proprietary DPCP ointment composition as a topical immunotherapeutic agent for the treatment of extensive alopecia areata.

Conditions

Alopecia Areata

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Alopecia Areata That Have Increased Hair Growth as Assessed by SALT Score

  Efficacy will be assessed as follows; a. Severity of Alopecia tool (SALT) score: Percentage of hair loss on the scalp will be determined using he SALT score, a global alopecia areata severity score based on scalp hair loss. The SALT score is calculated by visually examining four descrete areas of the scalp, measuring the percentage of terminal hair loss in each area. b. Scalp Photograhpy. c. Hair pull tests (positive or negative)

  18 weeks

Secondary Outcomes (2)

• Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

  18 weeks

• Determine the Best Starting Dose Range for Future Studies

  18 weeks

Study Arms (1)

Diphenylcyclopropenone (DPCP) Ointment

OTHER

All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks

Drug: Diphenylcyclopropenone (DPCP) Ointment

Interventions

Diphenylcyclopropenone (DPCP) Ointment DRUG

All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks

Diphenylcyclopropenone (DPCP) Ointment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject has clinical diagnosis of extensive alopecia areata (76%-99% involvement as determined by SALT score, Appendix B, Part I).
• Written informed consent and HIPAA authorization have been obtained.
• Subject is \> 18 to years of age.
• Female subjects of childbearing potential have a negative pregnancy test and agree to use an acceptable, highly effective method of birth control (i.e., failure rate of less than 1% per year) to prevent pregnancy.
• Subject agrees to comply with protocol requirements and attend all required study visits and is considered to be a good study subject.
• Subject meets concomitant medication washout requirements

You may not qualify if:

• Subject has \<76 or greater than 99% hair loss.
• Subject is pregnant or lactating.
• Subject has current controlled or uncontrolled bacterial, viral (with the exception of herpes simplex), fungal, atypical, or opportunistic infection(s).
• Subject has a history of substance abuse within the past five years.
• Immunosuppression (history of transplantation, chemotherapy, splenectomy, HIV).
• Administration of systemic treatment (e.g., Imuran, biologics) that have an immunomodulatory mechanism of action in the preceding 3 months.
• Previous treatment with DPCP.
• Application of topical immunomodulating agent in the preceding 6 weeks.
• Application of topical or intralesional corticosteroids within the past 6 weeks.
• Systemic (oral, inhaled, or intravenous) administration of corticosteroid or other systemic treatment (i.e., prednisone) with an immunosuppressive mechanism of action within the past 3 months.
• Use of light treatments (e.g., PUVA, narrow band UVB) in the preceding 6 weeks.
• Use of Anthralin in preceding 6 weeks.
• Use of minoxidil, topical or oral, in the preceding 4 weeks.
• Subject is currently or has undergone systemic therapy for malignancy within the past five years except for adequately treated Squamous Cell Carcinoma (SCC) or Basal Cell Carcinoma (BCC) of the skin.
• Clinical evidence of secondary skin infection (i.e., folliculitis).

Sponsors & Collaborators

• University of Minnesota: lead
• National Alopecia Areata Foundation: collaborator

Study Sites (1)

University of Minnesota Department of Dermatology

Minneapolis, Minnesota, 55455, United States

Location

MeSH Terms

Conditions

Alopecia Areata

Interventions

diphenylcyclopropenone; Ointments

Condition Hierarchy (Ancestors)

Alopecia; Hypotrichosis; Hair Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Dosage Forms; Pharmaceutical Preparations

Results Point of Contact

• Title: Maria Hordinsky, MD
• Organization: University of Minnesota

hordi001@umn.edu

612-625-9427

Study Officials

• Maria Hordinsky, MD

  University of MN Department of Dermatology

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 3, 2018
• First Posted: August 29, 2018
• Study Start: April 1, 2024
• Primary Completion: September 1, 2024
• Study Completion: September 1, 2024
• Last Updated: January 26, 2026
• Results First Posted: January 26, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)